Gatifloxacin (CAS 112811-59-3)
See product citations (14)
QUICK LINKS
Gatifloxacin, a fluoroquinolone antibiotic, is highly valued for its efficacy in combating various bacterial infections. It belongs to a class of antibiotics known for their broad-spectrum action. It showcases effectiveness against both gram-positive and gram-negative bacteria, making it an invaluable tool in combating a wide range of bacterial strains. In addition to its broad-spectrum nature, gatifloxacin also demonstrates utility in addressing specific mycobacterial infections. The mechanism underlying gatifloxacin′s antibacterial action centers on the inhibition of DNA gyrase, a bacterial enzyme responsible for the replication and transcription of DNA. By impeding this enzyme′s function, gatifloxacin effectively disrupts bacterial replication and transcription processes, ultimately leading to the demise of the bacteria.
Gatifloxacin (CAS 112811-59-3) References
- Gatifloxacin. | Perry, CM., et al. 1999. Drugs. 58: 683-96; discussion 697-8. PMID: 10551438
- Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae. | Fukuda, H., et al. 2001. Antimicrob Agents Chemother. 45: 1649-53. PMID: 11353607
- Gatifloxacin-associated acute hepatitis. | Henann, NE. and Zambie, MF. 2001. Pharmacotherapy. 21: 1579-82. PMID: 11765309
- Gatifloxacin in combination with rifampicin in a murine tuberculosis model. | Cynamon, M., et al. 2007. J Antimicrob Chemother. 60: 429-32. PMID: 17561504
- Gatifloxacin affects GLUT1 gene expression and disturbs glucose homeostasis in vitro. | Ge, TF., et al. 2007. Eur J Pharmacol. 573: 70-4. PMID: 17727838
- Gatifloxacin-associated hypoglycemia. | Ali, T., et al. 2007. J Okla State Med Assoc. 100: 425-8. PMID: 18183859
- Gatifloxacin produces both hypoglycemia and hyperglycemia: a retrospective study. | Haerian, H., et al. 2008. Am J Med Sci. 335: 95-8. PMID: 18277115
- Gatifloxacin for short, effective treatment of multidrug-resistant tuberculosis. | Chiang, CY., et al. 2016. Int J Tuberc Lung Dis. 20: 1143-7. PMID: 27510237
- Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis. | Deshpande, D., et al. 2018. Clin Infect Dis. 67: S274-S283. PMID: 30496459
- Ultrasound-assisted gatifloxacin delivery in mouse cornea, in vivo. | Jegal, U., et al. 2019. Sci Rep. 9: 15532. PMID: 31664145
- Toxicity, biodegradation of moxifloxacin and gatifloxacin on Chlamydomonas reinhardtii and their metabolic fate. | Wan, L., et al. 2022. Ecotoxicol Environ Saf. 240: 113711. PMID: 35653971
- Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. | Bauernfeind, A. 1997. J Antimicrob Chemother. 40: 639-51. PMID: 9421311
- Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms. | Ednie, LM., et al. 1998. Antimicrob Agents Chemother. 42: 2459-62. PMID: 9736586
- Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases. | Takei, M., et al. 1998. Antimicrob Agents Chemother. 42: 2678-81. PMID: 9756776
- Primary targets of fluoroquinolones in Streptococcus pneumoniae. | Fukuda, H. and Hiramatsu, K. 1999. Antimicrob Agents Chemother. 43: 410-2. PMID: 9925547
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Gatifloxacin, 1 g | sc-204762 | 1 g | $62.00 | |||
Gatifloxacin, 5 g | sc-204762A | 5 g | $270.00 |